Fairvalue-Calculator Fairvalue-Calculator
EN DE

Guizhou Xinbang Pharmaceutical Co (002390) Fair Value & Analysis

Healthcare · CN · Market cap 105B KRW

Price6,920 KRW
Fair Value8,246 KRW
Upside+19.2%
Quality95/100
Evidence: Medium Range 6,185 KRW – 10,308 KRW

Analysis

Guizhou Xinbang Pharmaceutical Co (002390) currently trades at 6,920 KRW, while our model-based Fair Value estimate is 8,246 KRW — implying the stock looks roughly 19.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Guizhou Xinbang Pharmaceutical Co., Ltd. manufactures and sells traditional Chinese medicine and other pharmaceutical products in China and internationally. The company cardiovascular and cerebrovascular, digestive system, endocrine, tumors and immunomodulatory drugs, blood system drugs, rheumatism and rheumatoid arthritis, urinary system, antipyretic and analgesic, cold medicine, gynecological medications, and anti-infective drugs. It also provides medical services. The company was founded in 1995 and is headquartered in Guiyang, China.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -81%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.